ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 2,804 shares of ResMed stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $84.17, for a total value of $236,012.68. Following the sale, the insider now directly owns 97,257 shares in the company, valued at approximately $8,186,121.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Pendarvis also recently made the following trade(s):

  • On Friday, November 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $82.20, for a total value of $523,120.80.
  • On Tuesday, October 3rd, David Pendarvis sold 6,364 shares of ResMed stock. The shares were sold at an average price of $76.94, for a total value of $489,646.16.

Shares of ResMed Inc. (NYSE:RMD) traded up $0.78 during trading hours on Tuesday, reaching $84.35. The company had a trading volume of 588,407 shares, compared to its average volume of 854,959. ResMed Inc. has a 1 year low of $58.71 and a 1 year high of $87.81. The company has a market capitalization of $11,860.00, a PE ratio of 29.35, a price-to-earnings-growth ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The firm had revenue of $523.66 million for the quarter, compared to analysts’ expectations of $506.08 million. During the same quarter in the previous year, the company earned $0.62 earnings per share. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. equities analysts predict that ResMed Inc. will post 3 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Investors of record on Thursday, November 9th will be issued a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 annualized dividend and a yield of 1.66%. ResMed’s payout ratio is 56.68%.

A number of research firms have recently weighed in on RMD. Barclays lifted their price target on ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Friday, October 27th. Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a report on Tuesday, August 8th. Jefferies Group reaffirmed a “sell” rating and set a $56.00 price target on shares of ResMed in a report on Thursday, October 12th. BMO Capital Markets lifted their price target on ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a report on Friday, October 27th. Finally, Zacks Investment Research cut ResMed from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $67.57.

Large investors have recently made changes to their positions in the stock. Creative Planning grew its position in ResMed by 97.1% in the second quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock worth $130,000 after buying an additional 823 shares during the last quarter. Strs Ohio grew its position in ResMed by 2.5% in the second quarter. Strs Ohio now owns 21,436 shares of the medical equipment provider’s stock worth $1,669,000 after buying an additional 523 shares during the last quarter. NGAM Advisors L.P. grew its position in ResMed by 3.4% in the second quarter. NGAM Advisors L.P. now owns 15,507 shares of the medical equipment provider’s stock worth $1,208,000 after buying an additional 504 shares during the last quarter. Janney Montgomery Scott LLC grew its position in ResMed by 6.4% in the second quarter. Janney Montgomery Scott LLC now owns 15,459 shares of the medical equipment provider’s stock worth $1,204,000 after buying an additional 935 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its position in ResMed by 9.1% in the second quarter. Daiwa Securities Group Inc. now owns 4,200 shares of the medical equipment provider’s stock worth $327,000 after buying an additional 350 shares during the last quarter. 62.02% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ResMed Inc. (RMD) Insider Sells $236,012.68 in Stock” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2017/12/05/resmed-inc-rmd-insider-sells-236012-68-in-stock.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.